Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > CD73 > CD3-H52H7

Human CD73 / NT5E Protein, His Tag (HPLC-verified) (active enzyme)

Order Now

  • Synonym
    CD73,NT5E,5'-Nucleotidase,5'-NT,NT5,NTE
  • Source
    Human CD73 Protein, His Tag(CD3-H52H7) is expressed from human 293 cells (HEK293). It contains AA Trp 27 - Ser 549 (Accession # P21589-1).
    Predicted N-terminus: Trp 27
  • Molecular Characterization
    CD73 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 59.9 kDa. The protein migrates as 65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-HPLC.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 120 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
CD73 SDS-PAGE

Human CD73 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-HPLC
CD73 SEC-HPLC

The purity of Human CD73 Protein, His Tag (Cat. No. CD3-H52H7) was greater than 90% as determined by SEC-HPLC.

Bioactivity-ELISA
 CD73 ELISA

Immobilized Human CD73 Protein, His Tag (Cat. No. CD3-H52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD73 Antibody, Human IgG1 with a linear range of 0.15-5 ng/mL (QC tested).

Bioactivity-SPR
 CD73 SPR

Anti-CD73 antibody (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD73 Protein, His Tag (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Bioactivity-BLI
 CD73 BLI

Loaded Anti-CD73 MAb (Human IgG1) on AHC Biosensor, can bind Human CD73 Protein, His Tag (Cat. No. CD3-H52H7) with an affinity constant of 0.179 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity

Measured by its ability to hydrolyze the 5’-phosphate group from the substrate adenosine-5’-monophosphate (AMP). The specific activity is >100000pmol/min/μg (QC tested).

  • Background
    5'-nucleotidase (5'-NT), also known as ecto-5'-nucleotidase or CD73 (cluster of differentiation 73), is an enzyme that is encoded by the NT5E gene. CD73 commonly serves to convert AMP to adenosine. Ecto-5-prime-nucleotidase (5-prime-ribonucleotide phosphohydrolase) catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. Other forms of 5-prime nucleotidase exist in the cytoplasm and lysosomes and can be distinguished from ecto-NT5 by their substrate affinities, requirement for divalent magnesium ion, activation by ATP, and inhibition by inorganic phosphate. Rare allelic variants are associated with a syndrome of adult-onset calcification of joints and arteries (CALJA) affecting the iliac, femoral, and tibial arteries reducing circulation in the legs and the joints of the hands and feet causing pain.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $120.00

Price(USD) : $350.00

Price(USD) : $1320.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:29 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message